Experimental Drugs for the Treatment of Hepatitis D.

Published in: Journal of experimental pharmacology (2021)

Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Antiviral treatment is urgently needed to prevent patients from developing end stage liver disease or hepatocellular carcinoma. Treatment options were limited to off-label use of pegylated interferon alfa until conditional approval of bulevirtide by the EMA (European Medicines Agency) in July 2020. However, several other antiviral compounds are currently investigated and represent promising agents for the treatment of chronic HDV infection.

Keyphrases

end stage renal disease
sars cov
chronic kidney disease
ejection fraction
early onset
combination therapy
prognostic factors
replacement therapy
patient reported outcomes
smoking cessation